individualised antisense oligonucleotides (ASOs)

antisense oligonucleotide therapy · EveryONE Medicines Inc.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for individualised antisense oligonucleotides (ASOs), covering 2026-03-17 to 2026-03-17. Get the full timeline:

Most recent: Clinical Trial Update: Investigation of Individualised Antisense Oligonucleotides (ASOs) in People With Unique Genetic Variants Causing Severely Debilitating, Life Threatening (SDLT) Central Nervous System (CNS) Conditions [Phase 1, Phase 2]

See pricing